Amgen (AMGN) Announces Presentation of Prolia Phase 3 Data in Osteoporosis
Tweet Send to a Friend
Amgen (NASDAQ: AMGN) announced results from a new exploratory analysis of the open-label extension study of the pivotal Phase 3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
